Last reviewed · How we verify
Placebo to match Add-back
This drug is a placebo used to match an add-back therapy.
This drug is a placebo used to match an add-back therapy. Used for Matching placebo for add-back therapy.
At a glance
| Generic name | Placebo to match Add-back |
|---|---|
| Sponsor | ObsEva SA |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
As a placebo, it does not have a specific mechanism of action. It is used to provide a control group in clinical trials for the add-back therapy.
Approved indications
- Matching placebo for add-back therapy
Common side effects
Key clinical trials
- Extension to Study on Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain (EDELWEISS 6) (PHASE3)
- Extension to Study on Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain (PHASE3)
- Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain. (PHASE3)
- A Phase 3 Study to Confirm the Efficacy and Safety of Linzagolix to Treat Endometriosis-associated Pain (PHASE3)
- Neurovascular Transduction During Exercise in Chronic Kidney Disease (PHASE2)
- Study of Relugolix With Estradiol and Norethindrone Acetate in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids (PHASE3)
- LIBERTY 2: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids (PHASE3)
- LIBERTY 1: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo to match Add-back CI brief — competitive landscape report
- Placebo to match Add-back updates RSS · CI watch RSS
- ObsEva SA portfolio CI